RMi Pre-opening: Friday, the 13th

March 13, 2026 8:25am

Gauging expectation … questionable yet …

I’d put blinders on and stay out of the way and put $$ to work

Get some, go with the flow!

Remember that overnight action in futures don't necessarily translate into actual trading in today’s regular stock market session.

Never leave retail investor uninformed … I say what others won’t, so you can KNOW what others can’t! 

Say/write less, mean more …

Thursday’s RMi Closing Bell: Wipe-out, econs and oil drop the sector… again … https://www.regmedinvestors.com/articles/14346

I chose to speak-up when many analysts, brokers and commentators have shut-up!

Friday: The pre-open Dow futures are UP +0.41% or (+193 points), the S&P futures are UP +0.40% or (+26 points) and the Nasdaq futures are UP +0.42% or (+8103 points)

• U.S. stock futures are ticking higher, Friday 3/13
• European markets traded lower,
• Asia Pacific markets dived

Economic Data: Multiple

8:30 am                GDP (first revision)          Q4                          1.5%      1.4%

8:30 am                Personal income               Jan.                        0.5%      0.4%

8:30 am                Consumer spending        Jan.                        0.3%      0.3%

8:30 am                PCE index (delayed report)          Jan.                        0.3%      0.4%

8:30 am                PCE (year-over-year)                                      2.9%      2.9%

8:30 am                Core PCE index  Jan.                        0.4%      0.4%

8:30 am                Core PCE (year-over-year)                                            3.1%      3.0%

8:30 am                Durable-goods orders    Jan.                        1.3%      -1.4%

8:30 am                Durable-goods minus transportation       Jan.                        --             0.9%

10:00 am             Job openings      Jan.                        6.7 million           6.5 million

10:00 am             Consumer sentiment (prelim)    March                   55.3        56.6

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

• Thursday: The Dow closed DOWN -739.42 points or -1.56%, the S&P closed DOWN -103.18 points or -1.52% while the Nasdaq closed DOWN -404.155 points or -1.78%
• Wednesday: The Dow closed DOWN -289.24 points or -0.61%, the S&P closed DOWN -5.68 points or -0.08 while the Nasdaq closed UP +19.031 points or +0.08%
• Tuesday: The Dow closed DOWN -34.29 points or -0.07%, the S&P closed DOWN -14.49 points or -0.21% while the Nasdaq closed UP +1.158 points or +0.01%
• Monday: The Dow closed UP +239.25 points or +0.50%, the S&P closed UP +55.97 points or +0.83% while the Nasdaq closed UP +308.267 points or +1.38%

• Last Friday’s (my) 40-company covered sector’s advance/decline line opened negative with 7 incliners, 30 decliners and 3 flats, ending with a negative close of 14 incliners, 24 decliners and 2 flats

• Last week: The S&P 500 was down -2%, the Dow -0.3% and the Nasdaq was down -1.2%.
• The previous week: The Dow finished down -1.3% for the week, the NASDAQ declined 0.9%, and the S&P 500 slipped -2%. 
• February: the Dow inclined +0.2%, the Nasdaq dived -3.3% and S&P 500 declined -1%.

Q1/26 – Q1 – March – 3 positive and 6 negative closes

• February – 1 market holiday, 11 positive and 8 negative closes
• January – 2 holiday, 2 neutral, 9 negative and 9 positive closes 

Q4/25:

• December, 1 holiday, 8 positive and 12 negative closes
• November, 1 holiday, 8 positive and 11 negative sessions
• October, 1 neutral, 10 positive and 12 negative closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

• Multiple earnings coming as sector releases Qs and FY25 …
• +Econs

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

The …if Strait of Hormuz sees sustained impairment beyond two or three months, that “becomes a real problem.”

Rising crude prices and growing inflation fears have also dampened investors’ expectations for Federal Reserve interest rate cuts this year.

Traders are now awaiting the release of January’s PCE … personal consumption expenditures price index — the Fed’s preferred inflation gauge readying for a read, today.

• The Dow consensus calls for PCE to gain +0.3% on a month-to-month basis and 2.9% from 12 months earlier. The estimate for core PCE, which excludes energy and food prices, is anticipated to have gained 0.4% for the month and 3.1% from a year earlier.

The 3 major averages are on pace for losses on the week. The S&P 500 is on track for a 1% decline, while the Dow is heading for a 1.7% slide. The Nasdaq is off 0.3% week to date.

“I hate to be considered negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Are the dice … hot, as they say it is STILL a “crap shoot”        

• Keep that in mind   the latest batch of buying opportunities. If you take advantage, you have to be nimble,  and turning losers into  winners. 

Investors has been looking for further insight into sector earnings; the Q4 and FY25 earnings reporting cycle. So far …

• Tuesday - 2/24 – AxoGen (AXGN), Beam Therapeutics (BEAM) and Supernus Therapeutics (SUPN)
• Wednesday – 2/25 – MiMedx (MDXG), Ionis Pharmaceuticals (IONS) and Sarepta Therapeutics (SRPT)
• Thursday – 2/26 – Intellia Therapeutics (NTLA), Wave Life Sciences (WVE), Mesoblast (MESO), Vericel (VCEL) and BioLife Solutions (BLFS)
• Monday – 3/2 uniQure NV (QURE)
• Thursday - 3/5 Regenxbio (RNX)
• Tuesday – 3/10 – BioNTech, SE (BNTX)

Welcome to my world of defining the “grey’ in our universe!

March – 2nd week

• 3/12 – Thursday closed negative with 1 incliner, 36 decliners and 3 flats
• 3/11 - Wednesday closed negative with 11 incliners, 26 decliners
• 3/10 - Tuesday closed positive with 21 incliners, 16 decliners and 3 flats
• 3/9 - Monday closed positive with 35 incliners, 2 decliners and 3 flats

March – 1st week

• 3/6 - Friday closed negative with 14 incliners, 24 decliners and 2 flats
• 3/5 – Thursday closed negative with 7 incliners, 32 decliners and 1 flat
• 3 /4 – Wednesday closed positive with 32 incliners, 6 decliners and 2 flats
• 3/3 - Tuesday closed negative with 2 incliners, 36 decliners and 2 flats
• 3/2 - Monday closed negative with 15 incliners, 23 decliners and 3 flats

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.